Urothelial carcinoma: variant histology does not influence outcomes with trimodality bladder-sparing treatment

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • No difference in response to induction chemoradiation between pure (PUC) and variant (VUC) urothelial carcinoma. 

 

Why this matters

  • Largest study to date describing the response of VUC to trimodality bladder-sparing therapy (TMT).

Key results

  • 250 (83%) patients had complete response to induction chemoradiation. 
  • No difference in rates of response between PUC and VUC (83% vs 82%; P=.9). 
  • No patient required radical cystectomy for treatment-related toxicity. 
  • 1-y, 5-y, and 10-y salvage cystectomy rates were 10%, 19%, and 24%, respectively in PUC vs 15%, 28%, and 28%, respectively in VUC (P=.3). 
  • 5-y and 10-y cumulative disease-specific survival (DSS) were 75% and 67% in PUC, vs 64% each in VUC (P=.4). 
  • 5-y and 10-y OS were 61% and 42%, vs 52% and 42% (P=.2). 
  • Bladder-intact DSS was not significantly different between VUC and PUC (P=.3). 
  • In a multivariable model, VUC was not associated with survival. 
  • Age, stage, hydronephrosis, and response to induction chemoradiation were significant predictors of OS. 
  • Hydronephrosis and incomplete response to induction therapy were associated with worse DSS. 

Study design

  • Retrospective study of 303 patients treated with TMT between 1993 and 2013. 
  • Funding: None.

Limitations

  • Single institution experience. 
  • Small sample sizes. 
  • Limited to transurethral resection of the bladder tumor specimens.